Patents by Inventor Wolfgang Schueler
Wolfgang Schueler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067681Abstract: The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.Type: ApplicationFiled: October 24, 2023Publication date: February 29, 2024Applicant: Valneva SEInventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
-
Publication number: 20230322869Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: January 6, 2023Publication date: October 12, 2023Applicant: Valneva Austria GmbHInventors: URBAN LUNDBERG, Wolfgang Schüler
-
Publication number: 20230295245Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 14, 2022Publication date: September 21, 2023Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20230151063Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.Type: ApplicationFiled: April 13, 2018Publication date: May 18, 2023Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
-
Patent number: 11572392Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: August 11, 2020Date of Patent: February 7, 2023Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 11466058Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: December 4, 2019Date of Patent: October 11, 2022Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20220185847Abstract: The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections.Type: ApplicationFiled: May 19, 2020Publication date: June 16, 2022Applicant: Valneva SEInventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
-
Publication number: 20220185851Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: November 2, 2021Publication date: June 16, 2022Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Patent number: 11208439Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: February 27, 2018Date of Patent: December 28, 2021Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20210054032Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: August 11, 2020Publication date: February 25, 2021Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 10766931Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: April 4, 2018Date of Patent: September 8, 2020Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Publication number: 20200239525Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: December 4, 2019Publication date: July 30, 2020Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Patent number: 10544194Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: September 22, 2016Date of Patent: January 28, 2020Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20180362593Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: April 4, 2018Publication date: December 20, 2018Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Publication number: 20180327460Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: February 27, 2018Publication date: November 15, 2018Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Patent number: 9975927Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: January 9, 2015Date of Patent: May 22, 2018Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 9926343Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: September 16, 2016Date of Patent: March 27, 2018Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20170107263Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 16, 2016Publication date: April 20, 2017Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20170101446Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 22, 2016Publication date: April 13, 2017Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20160333056Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: January 9, 2015Publication date: November 17, 2016Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler